Myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186rhenium-(tin)1,1- hydroxyethylidene diphosphonate (186Re-HEDP).
D004999:Amifostine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D001792:Blood Platelets / Q000528:radiation effects; D001853:Bone Marrow / Q000187:drug effects* / Q000502:physiology* / Q000528:radiation effects; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007962:Leukocytes / Q000528:radiation effects; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging / Q000379:methods; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics; D013997:Time Factors
D009942:Organometallic Compounds; D011837:Radiation-Protective Agents; D019275:Radiopharmaceuticals; C064573:rhenium-186(tin)etidronate; D012968:Etidronic Acid; D004999:Amifostine